{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:58:46Z","timestamp":1790758726484,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016083","name":"Hebei Provincial Department of Human Resources and Social Security","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017959","name":"Health Commission of Hebei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201973"],"award-info":[{"award-number":["82201973"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.heliyon.2023.e20690","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T05:27:04Z","timestamp":1696829224000},"page":"e20690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R\/T790M or L858R\/S768I mutations: Two case reports"],"prefix":"10.1016","volume":"9","author":[{"given":"Guangrui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8816-475X","authenticated-orcid":false,"given":"Mei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-7625","authenticated-orcid":false,"given":"Xiaocui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-4626","authenticated-orcid":false,"given":"Panpan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-7823","authenticated-orcid":false,"given":"Fengjun","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2023.e20690_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e20690_bib2","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/ijc.21940","article-title":"Frequent EGFR mutations in brain metastases of lung adenocarcinoma","volume":"119","author":"Matsumoto","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e20690_bib3","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/annonc\/mdn679","article-title":"Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer","volume":"20","author":"Gow","year":"2009","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e20690_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11864-020-00759-3","article-title":"Leptomeningeal metastases in non-small cell lung cancer: optimal systemic management in NSCLC with and without driver mutations","volume":"21","author":"Alexander","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e20690_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy","volume":"31","author":"Park","year":"2020","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e20690_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN clinical Practice Guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e20690_bib7","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e20690_bib8","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","article-title":"Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA)","volume":"3","author":"Sperduto","year":"2017","journal-title":"JAMA Oncol."},{"issue":"14","key":"10.1016\/j.heliyon.2023.e20690_bib9","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.heliyon.2023.e20690_bib10","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-07-5030","article-title":"Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms","volume":"14","author":"Bell","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e20690_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5732\/cjc.011.10106","article-title":"East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians","volume":"30","author":"Zhou","year":"2011","journal-title":"Chin. J. Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e20690_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cllc.2018.03.015","article-title":"Dynamics of EGFR mutation load in plasma for prediction of treatment response and disease progression in patients with EGFR-mutant lung adenocarcinoma","volume":"19","author":"Taus","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e20690_bib13","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1158\/1078-0432.CCR-21-2840","article-title":"Circulating cell-free DNA as a prognostic biomarker in patients with advanced ALK+ non-small cell lung cancer in the global phase III ALEX trial","volume":"28","author":"Dziadziuszko","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.heliyon.2023.e20690_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163923","article-title":"The liquid biopsy for lung cancer: state of the art, limitations and future developments","volume":"13","author":"Di Capua","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e20690_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtho.2018.10.008","article-title":"Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced non-small cell lung cancer","volume":"14","author":"Schrock","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"28","key":"10.1016\/j.heliyon.2023.e20690_bib16","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e20690_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010146","article-title":"First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer?","volume":"20","author":"Takeda","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e20690_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/JTO.0000000000000069","article-title":"EGFR mutation and brain metastasis in pulmonary adenocarcinomas","volume":"9","author":"Shin","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2023.e20690_bib19","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jiph.2012.09.008","article-title":"EGFR mutation testing in non-small cell lung cancer (NSCLC)","volume":"5","author":"Al Dayel","year":"2012","journal-title":"J Infect Public Health"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e20690_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040316","article-title":"Structure and dynamics of the EGF receptor as revealed by experiments and simulations and its relevance to non-small cell lung cancer","volume":"8","author":"Martin-Fernandez","year":"2019","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e20690_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e20690_bib22","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1158\/0008-5472.CAN-16-3404","article-title":"Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors","volume":"77","author":"Kosaka","year":"2017","journal-title":"Cancer Res."},{"issue":"216","key":"10.1016\/j.heliyon.2023.e20690_bib23","doi-asserted-by":"crossref","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e20690_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2017.11.005","article-title":"A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer","volume":"114","author":"Tu","year":"2017","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e20690_bib25","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-20-0103","article-title":"Osimertinib, an irreversible next-generation EGFR tyrosine kinase inhibitor, exerts antitumor activity in various preclinical NSCLC models harboring the uncommon EGFR mutations G719X or L861Q or S768I","volume":"19","author":"Floc'h","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2023.e20690_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.999606","article-title":"Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation","volume":"12","author":"Dong","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e20690_bib27","first-page":"113","article-title":"Successful treatment of a patient with lung adenocarcinoma harboring compound EGFR gene mutations, G719X and S768I, with afatinib","volume":"45","author":"Kutsuzawa","year":"2020","journal-title":"Tokai J. Exp. Clin. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e20690_bib28","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated t790m-positive advanced non-small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e20690_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11523-018-0612-z","article-title":"Liquid-biopsy-based identification of EGFR T790M mutation-mediated resistance to afatinib treatment in patients with advanced EGFR mutation-positive NSCLC, and subsequent response to osimertinib","volume":"14","author":"Hochmair","year":"2019","journal-title":"Target Oncol"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e20690_bib30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jtho.2017.05.002","article-title":"EGFR mutation analysis for prospective patient selection in two phase II registration studies of osimertinib","volume":"12","author":"Jenkins","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.heliyon.2023.e20690_bib31","article-title":"Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: an updated database of 1023 cases brief report","volume":"12","author":"Yang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2023.e20690_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1011092","article-title":"Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation","volume":"13","author":"Ko","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e20690_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/curroncol29010024","article-title":"Uncommon EGFR compound mutations in non-small cell lung cancer (NSCLC): a systematic review of available evidence","volume":"29","author":"Attili","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.heliyon.2023.e20690_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920946156","article-title":"The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation","volume":"12","author":"Wu","year":"2020","journal-title":"Ther Adv Med Oncol"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023078982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023078982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:13:33Z","timestamp":1790756013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023078982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2405844023078982"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20690","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R\/T790M or L858R\/S768I mutations: Two case reports","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e20690"}}